A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the response rate of cetuximab plus irinotecan combination therapy in subjects
with EGFR-detectable metastatic colorectal carcinoma who have documented progressive disease
to irinotecan-based chemotherapy and who have failed (progressive disease or intolerance)
previous oxaliplatin-based and fluoropyrimidine-based chemotherapies.